Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A.

Related Articles

Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A.

Oncoimmunology. 2016;5(11):e1239006

Authors: Casey NP, Fujiwara H, Ochi T, Yasukawa M

Abstract
Adult T-cell leukemia/lymphoma is caused by infection with HTLV-1, following a long latent period. Immunotherapy targeting Aurora kinase A, a tumor-associated antigen over-expressed in adult T-cell leukemia/lymphoma, holds great therapeutic potential. We review the evidence in favor of a therapeutic strategy combining vaccination and TCR-gene transfer against this target.

PMID: 27999761 [PubMed]

http://ift.tt/2i4EhoO